UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
(Amendment No. 1)
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of December 2019
011-36000
(Commission File Number)
XTL Biopharmaceuticals Ltd.
(Exact name of Registrant as specified in its charter)
5 Badner St.
Ramat Gan, Israel, 5218102
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
EXPLANATORY NOTE
On December 18, 2019, XTL Biopharmaceuticals Ltd. (the “Company”) filed a Current Report on Form 6-K announcing that it will hold an Annual General Meeting of Shareholders (the “Annual Meeting”) on January 22, 2020 at 10:00 a.m. (Israel time) (the “Original Report”). This Amendment No. 1 on Form 6-K/A (the “Amendment”) is being furnished to replace Exhibit 99.1 of the Original Report (the “Original Notice and Proxy Statement”), to amend and restate the Original Notice and Proxy Statement solely to correct a scrivener’s error to disclose that the correct exercise price of options to be issued to Chief Executive Officer appointee Doron Turgeman is NIS 0.09 per option, not NIS 0.9 per option as set forth in the Original Notice and Proxy Statement. Other than as expressly set forth above, this Amendment No. 1 does not, and does not purport to, amend, update or restate the information in any other item of the Original Report, or reflect any events that have occurred after the Original Report was originally filed.
1
Exhibit Index
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
XTL BIOPHARMACEUTICALS LTD. | ||
Date: January 13, 2020 | By: | /s/ Josh Levine |
Josh Levine | ||
Chief Executive Officer |
3